Vanda Pharmaceuticals (NASDAQ:VNDA) Lowered to “Hold” Rating by Zacks Research

Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other analysts have also weighed in on VNDA. B. Riley Financial raised their price objective on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, December 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, January 21st. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, January 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. Finally, HC Wainwright boosted their target price on shares of Vanda Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Vanda Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $13.63.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $6.10 on Wednesday. The company’s 50-day moving average price is $7.33 and its two-hundred day moving average price is $5.73. The firm has a market cap of $360.57 million, a P/E ratio of -1.64 and a beta of 0.62. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a 12 month low of $3.81 and a 12 month high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The firm had revenue of $57.22 million for the quarter, compared to analyst estimates of $59.28 million. On average, analysts anticipate that Vanda Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Torren Management LLC bought a new stake in Vanda Pharmaceuticals during the 4th quarter valued at $25,000. Russell Investments Group Ltd. increased its position in shares of Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 5,328 shares in the last quarter. CWM LLC increased its position in shares of Vanda Pharmaceuticals by 424.6% during the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 7,575 shares in the last quarter. Quarry LP bought a new position in Vanda Pharmaceuticals in the 3rd quarter valued at about $53,000. Finally, Cerity Partners LLC acquired a new position in Vanda Pharmaceuticals during the 2nd quarter valued at about $69,000. Institutional investors own 88.14% of the company’s stock.

More Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Wall Street bullishness: analysts on TipRanks highlight a potential ~126% upside tied to the upcoming Bysanti FDA decision, boosting investor optimism ahead of the PDUFA. TipRanks: FDA Calendar / VNDA
• Positive Sentiment: Brokerage sentiment supportive: several brokerages carry buy/moderate‑buy views (consensus “Moderate Buy”), which can sustain buying interest into the FDA decision. American Banking News: Consensus Rating
• Neutral Sentiment: Media attention: broad coverage and “heavy buzz” ahead of the FDA verdict is driving volume and volatility, a neutral factor that can amplify moves in either direction. MSN: Heavy Buzz Ahead of Verdict
• Negative Sentiment: Material earnings downgrades from HC Wainwright: the firm cut Q1–Q4 and FY2026 EPS sharply (FY2026 to ($1.65) from ($0.36)), signaling weaker near‑term profitability and raising downside risk if the FDA outcome is unfavorable. HC Wainwright still has a Buy and $22 target, but the forecast cuts increase execution risk. MarketBeat: HC Wainwright Estimates
• Negative Sentiment: Analyst caution: a Seeking Alpha piece frames the stock as “high risk, heavily discounted” ahead of PDUFA, warning that a negative decision or weaker commercial prospects could prompt sharp downside. Seeking Alpha: High Risk Ahead of PDUFA

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.